News

Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company`s move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets. Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Net profit of Venus Remedies rose 30.51% to Rs 25.58 crore in the quarter ended December 2025 as against Rs 19.60 crore during the previous quarter ended December 2024. Sales rose 2.12% to Rs 180.26 crore in the quarter ended December 2025 as against Rs 176.52 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales180.26176.52 2 OPM %20.8110.21 - PBDT40.0320.38 96 PBT33.4714.97 124 NP25.5819.60 31 Powered by Capital Market - Live News

Venus Remedies will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live News

Net profit of Venus Remedies rose 473.50% to Rs 20.13 crore in the quarter ended September 2025 as against Rs 3.51 crore during the previous quarter ended September 2024. Sales rose 13.32% to Rs 192.75 crore in the quarter ended September 2025 as against Rs 170.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales192.75170.10 13 OPM %16.064.45 - PBDT32.6615.48 111 PBT26.499.07 192 NP20.133.51 474 Powered by Capital Market - Live News